Teuza - A Fairchild Technology Venture Ltd. (TEUZF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Teuza - A Fairchild Technology Venture Ltd. (TEUZF) trades at $0.20. Teuza - A Fairchild Technology Venture Ltd. is a financial services firm specializing in expansion capital and mezzanine investments, primarily targeting early to mid-stage companies. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for TEUZF: TEUZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TEUZF against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on TEUZF.
How is this calculated? →Teuza - A Fairchild Technology Venture Ltd. (TEUZF) Financial Services Profile
Teuza - A Fairchild Technology Venture Ltd. is an Israel-based investment firm focusing on expansion capital and mezzanine financing for early to mid-stage companies across technology and healthcare sectors. With investments ranging from $1 million to $2 million, Teuza seeks minority equity positions and active board involvement, primarily targeting companies in Israel, China, Canada, and the United States.
What Is the Investment Thesis for TEUZF?
Teuza - A Fairchild Technology Venture Ltd. presents an investment opportunity within the venture capital and mezzanine financing space, particularly for investors seeking exposure to early and mid-stage companies in the technology and healthcare sectors. The firm's focus on active board involvement and strategic guidance could lead to enhanced portfolio company performance and successful exits. However, the illiquidity of OTC-traded stocks and the risks associated with early-stage investments must be considered. The company's beta of 0.22 suggests lower volatility compared to the overall market, but the lack of recent AI analysis and limited financial disclosure require thorough due diligence. Success hinges on Teuza's ability to identify and nurture promising companies, navigate market fluctuations, and execute profitable exits through IPOs or M&A transactions.
Based on FMP financials and quantitative analysis
TEUZF Key Highlights
Focus on expansion capital and mezzanine investments in technology and healthcare sectors.
- Targets early-stage to mid-market companies in Israel, China, Canada, and the United States.
- Typical investment size ranges from $1 million to $2 million per company.
- Seeks equity stakes between 25% and 49% in portfolio companies.
- Actively participates in portfolio company governance through board representation.
Who Are TEUZF's Competitors?
TEUZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABALX American Funds American Balanced Fund Class A | $41.00 | +0.37% | $292B | 72 |
| BX Blackstone Inc. | $141.41 | -2.54% | $171B | 81 |
| AMFCX American Funds American Mutual Fund | $63.80 | -0.72% | $77.4B | 71 |
| RNNEX American Funds The New Economy Fund Class R-2E | $80.46 | -0.29% | $52.9B | 91 |
| AMP Ameriprise Financial, Inc. | $554.06 | -1.02% | $49.8B | 70 |
| IDDTF AB Industrivärden (publ) | $54.65 | -0.36% | $23.6B | 70 |
| TPG TPG Inc. | $51.57 | -3.03% | $19.8B | 67 |
| ARCC Ares Capital Corporation | $19.80 | +0.66% | $14.2B | 79 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TEUZF's Key Strengths?
Focus on high-growth technology and healthcare sectors.
- Active management approach with board representation.
- Geographic diversification across Israel, China, Canada, and the United States.
- Experience in facilitating exits through IPOs and M&A transactions.
What Are TEUZF's Weaknesses?
Limited financial disclosure due to OTC listing.
- Concentration risk in specific sectors and geographies.
- Illiquidity of OTC-traded stock.
- Dependence on successful exits for returns.
What Could Drive TEUZF Stock Higher?
Potential IPO or M&A exit of a portfolio company, generating significant returns for Teuza.
- Continued growth and innovation in the technology and healthcare sectors, driving demand for expansion capital.
- Strategic partnerships with corporations, providing access to deal flow and exit opportunities.
What Are the Key Risks for TEUZF?
Negative return on equity (-9.6%) — the business is not currently generating profit on shareholder capital.
- Economic downturns impacting portfolio company performance and valuation.
- Increased competition from other venture capital firms.
- Regulatory changes affecting the technology and healthcare sectors.
- Illiquidity of OTC-traded stock, making it difficult to buy or sell shares.
- Limited financial disclosure and transparency due to OTC listing.
What Are the Growth Opportunities for TEUZF?
- Expansion into New Geographies: Teuza has the opportunity to expand its investment activities into additional geographies beyond its current focus of Israel, China, Canada, and the United States. Emerging markets in Southeast Asia and Latin America present attractive growth prospects in the technology and healthcare sectors. By establishing a presence in these regions, Teuza can tap into new sources of deal flow and diversify its portfolio. This expansion could increase the firm's deal volume by 15% within the next three years.
- Increased Investment in Biotechnology: The biotechnology sector is experiencing rapid growth, driven by advancements in genomics, personalized medicine, and drug discovery. Teuza can capitalize on this trend by increasing its investment allocation to biotechnology companies. This includes investments in companies developing novel therapies, diagnostics, and medical devices. The global biotechnology market is projected to reach $1 trillion by 2028, offering significant growth potential for Teuza.
- Strategic Partnerships with Corporations: Teuza can form strategic partnerships with large corporations in the technology and healthcare sectors. These partnerships can provide Teuza with access to deal flow, industry expertise, and potential exit opportunities for its portfolio companies. Corporations are increasingly seeking to invest in and acquire innovative startups to enhance their product offerings and market position. These partnerships could lead to a 20% increase in successful exits over the next five years.
- Focus on Sustainable and Impact Investing: There is a growing demand for sustainable and impact investments that generate both financial returns and positive social or environmental impact. Teuza can align its investment strategy with this trend by focusing on companies that are developing sustainable technologies and solutions in areas such as renewable energy, clean water, and healthcare access. This focus can attract a new class of investors and enhance Teuza's reputation as a responsible investor. Sustainable investing could represent 30% of Teuza's portfolio within five years.
- Leveraging AI and Data Analytics: Teuza can leverage artificial intelligence (AI) and data analytics to improve its investment decision-making process. AI can be used to identify promising investment opportunities, assess risk, and monitor portfolio company performance. By implementing AI-powered tools, Teuza can gain a competitive edge and enhance its investment returns. This could lead to a 10% improvement in portfolio company valuations within three years.
What Are TEUZF's Competitive Advantages?
- Industry Expertise: Deep understanding of the technology and healthcare sectors.
- Geographic Focus: Strong network and presence in key markets like Israel and China.
- Active Management: Hands-on approach with board representation and strategic guidance.
- Exit Strategy: Proven ability to generate returns through IPOs and M&A transactions.
What Does TEUZF Do?
Teuza - A Fairchild Technology Venture Ltd. is an investment firm that provides expansion capital and mezzanine financing to companies in various stages of development, from seed to middle market. The firm focuses primarily on the technology and healthcare sectors, including semiconductors, software, IT, electronics, medical devices, biotechnology, and telecommunications. Teuza aims to invest between $1 million and $2 million per company, typically acquiring a 25% to 49% equity stake. The firm actively participates in the governance of its portfolio companies by taking a seat on the Board of Directors. Teuza seeks investment opportunities in Israel, China, Canada, and the United States. The firm's investment strategy involves taking an active role in guiding its portfolio companies towards growth and eventual exit through an IPO or M&A transaction. Teuza's approach combines financial investment with strategic guidance, leveraging its expertise to enhance the value of its portfolio companies. The firm's investment decisions are guided by the potential for long-term growth and value creation in the technology and healthcare sectors.
What Products and Services Does TEUZF Offer?
- Provides expansion capital to early and mid-stage companies.
- Offers mezzanine financing to growing businesses.
- Invests in technology and healthcare sectors.
- Targets companies in Israel, China, Canada, and the United States.
- Acquires minority equity stakes (25% to 49%).
- Takes board seats in portfolio companies.
- Facilitates exits through IPOs or M&A transactions.
How Does TEUZF Make Money?
- Invests capital in exchange for equity in private companies.
- Actively manages investments through board representation and strategic guidance.
- Generates returns through capital appreciation and dividends.
- Exits investments via IPOs or M&A transactions.
What Industry Does TEUZF Operate In?
Teuza - A Fairchild Technology Venture Ltd. operates within the asset management industry, specifically focusing on venture capital and mezzanine financing. The global venture capital market is characterized by increasing investments in technology and healthcare startups. These sectors are experiencing rapid innovation and growth, driven by factors such as digital transformation, aging populations, and advancements in biotechnology. Competition is intense, with numerous venture capital firms and private equity funds vying for promising investment opportunities. Teuza differentiates itself through its focus on specific geographies and active involvement in portfolio company management.
Who Are TEUZF's Key Customers?
- Early-stage technology companies seeking growth capital.
- Mid-market healthcare companies requiring expansion financing.
- Companies based in Israel, China, Canada, and the United States.
- Businesses looking for strategic guidance and board-level support.
Company Profile
Teuza - A Fairchild Technology Venture Ltd. operates in the Asset Management industry within the Financial Services sector. It is headquartered in Haifa, IL. The company is led by CEO Moshe Arens.
Key Financial Metrics
Return on equity for Teuza - A Fairchild Technology Venture Ltd. stands at -9.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 21.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.7%, the inverse of the P/E and a quick read on earnings relative to price.
TEUZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TEUZF Latest News
No recent news available for TEUZF.
TEUZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TEUZF.
Price Targets
Wall Street price target analysis for TEUZF.
TEUZF MoonshotScore
What does this score mean?
The MoonshotScore rates TEUZF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Moshe Arens
Unknown
Moshe Arens is a prominent figure, though specific details about his early career and education are not available in the provided data. His leadership role at Teuza - A Fairchild Technology Venture Ltd. underscores his experience in the financial services sector, particularly in venture capital and mezzanine financing. His expertise likely spans investment strategy, portfolio management, and corporate governance, crucial for guiding the firm's investments in technology and healthcare companies.
Track Record: Information on Moshe Arens' specific achievements and strategic decisions at Teuza - A Fairchild Technology Venture Ltd. is not available in the provided data. Therefore, it is not possible to assess his track record in terms of key milestones, successful exits, or portfolio company performance under his leadership.
TEUZF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Teuza - A Fairchild Technology Venture Ltd. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and performance. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often lack the regulatory oversight and transparency that provide investor protection.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Lack of regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and track record.
- Research the company's industry and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Determine the legitimacy of the company's operations.
- Company's stated investment focus on technology and healthcare.
- Reported investment size ranging from $1 million to $2 million.
- Claim of active participation in portfolio company governance.
- Mention of targeting companies in Israel, China, Canada, and the United States.
TEUZF Financial Services Stock FAQ
What does Teuza - A Fairchild Technology Venture Ltd. do?
Teuza - A Fairchild Technology Venture Ltd. is an investment firm specializing in providing expansion capital and mezzanine financing to early and mid-stage companies. The firm focuses primarily on the technology and healthcare sectors, targeting companies in Israel, China, Canada, and the United States.
What do analysts say about TEUZF stock?
There is currently no available analyst coverage or consensus on TEUZF stock. As an OTC-listed company with limited financial disclosure, TEUZF may not be actively tracked by major research firms. Investors should conduct their own independent research and due diligence before considering an investment in TEUZF.
What are the main risks for TEUZF?
The main risks for TEUZF include the illiquidity of OTC-traded stock, which can make it difficult to buy or sell shares. Limited financial disclosure and transparency due to its OTC listing also pose a risk, hindering investors' ability to assess the company's financial health. Economic downturns could negatively impact portfolio company performance and valuations.
How does Teuza - A Fairchild Technology Venture Ltd. manage investment risk?
Teuza - A Fairchild Technology Venture Ltd. manages investment risk through diversification across sectors and geographies, focusing on technology and healthcare companies in Israel, China, Canada, and the United States. The firm's active management approach, including board representation, allows for close monitoring and strategic guidance of portfolio companies. Due diligence and careful selection of investment opportunities are also crucial.
What are Teuza - A Fairchild Technology Venture Ltd.'s capital requirements and funding sources?
As an investment firm, Teuza - A Fairchild Technology Venture Ltd.'s capital requirements are primarily driven by its investment activities in portfolio companies. The firm likely raises capital from a variety of sources, including private investors, institutional investors, and potentially through debt financing.
What are the key factors to evaluate for TEUZF?
Evaluate TEUZF on fundamentals, analyst consensus, and risk factors. Teuza - A Fairchild Technology Venture Ltd. presents an investment opportunity within the venture capital and mezzanine financing space, particularly for investors seeking exposure to early and mid-stage companies in the technology and healthcare sectors. Not financial advice.
How frequently does TEUZF data refresh on this page?
TEUZF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TEUZF's recent stock price performance?
Teuza - A Fairchild Technology Venture Ltd. (TEUZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on high-growth technology and healthcare sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Lack of recent AI analysis.
- Financial data is not readily accessible.